AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Quattro Financial Advisors LLC

Quattro Financial Advisors LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 7.7% in the 4th quarter, Holdings Channel reports. The firm owned 11,000 shares of the company’s stock after selling 922 shares during the quarter. AstraZeneca accounts for approximately 0.1% of Quattro Financial Advisors LLC’s portfolio, making the stock its 3rd biggest position. Quattro Financial Advisors LLC’s holdings in AstraZeneca were worth $721,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. grew its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca during the third quarter valued at about $28,000. Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca during the third quarter valued at about $45,000. Albion Financial Group UT grew its stake in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management grew its stake in shares of AstraZeneca by 38.4% during the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after acquiring an additional 192 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 1.3 %

NASDAQ:AZN opened at $68.96 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The stock has a 50-day simple moving average of $67.20 and a 200 day simple moving average of $73.72. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a market capitalization of $213.85 billion, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the company posted $0.87 earnings per share. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. Sell-side analysts predict that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.